Literature DB >> 17691981

The role of glutamate and its receptors in migraine.

Michail Vikelis1, Dimos D Mitsikostas.   

Abstract

Glutamate (Glu) is the principal excitatory neurotransmitter in the central nervous system. Its receptors are classified into ionotropic receptors, which are ion channels and include NMDA, AMPA and kainate receptors, named after the agonists that selectively bind to them, and metabotropic receptors, which are G-protein coupled receptors. The trigeminal system is considered to play a key role in migraine pathophysiology, trafficking pain signals from the head and face to the trigeminal nucleus caudalis. The role of glutamate in the pathophysiology of migraine is implicated by data from animal and human studies. Animal studies include experiments of cortical spreading depression, studies of c-fos protein expression in trigeminal nucleus caudalis, studies of plasma protein extravasation and electrophysiological studies. Human studies investigating the role of Glu in migraine pathogenesis measured the levels of Glu in plasma, platelets and cerebrospinal fluid, studied its effect on migraine symptoms and examined the effect of Glu in modulating sensitization. Findings from both the animal and the human studies suggest a link between glutamate and migraine and further suggest that glutamate plays a key role in migraine mechanisms. In the future, efforts should be made to further investigate the role of glutamate in migraine pathogenesis and, subsequently, in migraine treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17691981     DOI: 10.2174/187152707781387279

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  44 in total

Review 1.  Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms.

Authors:  Kenneth E Miller; E Matthew Hoffman; Mathura Sutharshan; Ruben Schechter
Journal:  Pharmacol Ther       Date:  2011-01-26       Impact factor: 12.310

Review 2.  Identification of molecular genetic factors that influence migraine.

Authors:  Bridget H Maher; Lyn R Griffiths
Journal:  Mol Genet Genomics       Date:  2011-04-26       Impact factor: 3.291

Review 3.  Transcranial magnetic simulation in the treatment of migraine.

Authors:  Richard B Lipton; Starr H Pearlman
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

4.  Serum MicroRNA Signatures in Migraineurs During Attacks and in Pain-Free Periods.

Authors:  Hjalte H Andersen; Meg Duroux; Parisa Gazerani
Journal:  Mol Neurobiol       Date:  2015-02-01       Impact factor: 5.590

5.  Pharmacology.

Authors:  Hayrunnisa Bolay; Paul Durham
Journal:  Handb Clin Neurol       Date:  2010

6.  Stereoselective Synthesis of New (2S,3R)-3-Carboxyphenyl)pyrrolidine-2-carboxylic Acid Analogues Utilizing a C(sp3)-H Activation Strategy and Structure-Activity Relationship Studies at the Ionotropic Glutamate Receptors.

Authors:  Silke Kayser; Jacob C Hansen; Markus Staudt; Aleksandra Moroz; Younes Larsen; Piero Temperini; Feng Yi; Jed T Syrenne; Niels Krogsgaard-Larsen; Stylianos Iliadis; Birgitte Nielsen; Kasper B Hansen; Darryl S Pickering; Lennart Bunch
Journal:  ACS Chem Neurosci       Date:  2020-02-17       Impact factor: 4.418

7.  A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.

Authors:  Gábor Veres; Annamária Fejes-Szabó; Dénes Zádori; Gábor Nagy-Grócz; Anna M László; Attila Bajtai; István Mándity; Márton Szentirmai; Zsuzsanna Bohár; Klaudia Laborc; István Szatmári; Ferenc Fülöp; László Vécsei; Árpád Párdutz
Journal:  J Neural Transm (Vienna)       Date:  2016-09-14       Impact factor: 3.575

8.  Excitatory neurotransmitters in brain regions in interictal migraine patients.

Authors:  Andrew Prescot; Lino Becerra; Gautam Pendse; Shannon Tully; Eric Jensen; Richard Hargreaves; Perry Renshaw; Rami Burstein; David Borsook
Journal:  Mol Pain       Date:  2009-06-30       Impact factor: 3.395

9.  Common variants in the regulative regions of GRIA1 and GRIA3 receptor genes are associated with migraine susceptibility.

Authors:  Daniela Formicola; Andrea Aloia; Simone Sampaolo; Olimpia Farina; Daria Diodato; Lyn R Griffiths; Fernando Gianfrancesco; Giuseppe Di Iorio; Teresa Esposito
Journal:  BMC Med Genet       Date:  2010-06-25       Impact factor: 2.103

10.  Prevalence and risk of migraine headaches in adult fragile X premutation carriers.

Authors:  J Au; R S Akins; L Berkowitz-Sutherland; H-T Tang; Y Chen; A Boyd; F Tassone; D V Nguyen; R Hagerman
Journal:  Clin Genet       Date:  2013-02-21       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.